According to John M. Burke, MD, it is hard to imagine that results presented at ESMO in the urothelial cancer space will not lead to the complete replacement of conventional chemotherapy as the standard first-line treatment.
John M. Burke, MD
Hematologist and Medical Oncologist
Rocky Mountain Cancer Centers
Associate Chair
US Oncology Hematology
Research Program Aurora, CO
In the last 20 years we have seen targeted therapies and immunotherapies emerge as effective treatments for cancer. In most cases, the rollout of such therapies has been in a relatively orderly fashion, starting with demonstrated benefit in heavily pretreated patients and then slowly moving forward as the therapies are compared with standard chemotherapy. And in some cases, novel therapies have completely replaced chemotherapy, making the latter obsolete.
At this year’s European Society for Medical Oncology (ESMO) meeting in Madrid, Spain, we learned that urothelial cancer may be next in line for such a paradigm shift. Many patients with metastatic urothelial cancer have comorbidities, often including renal impairment, which prevent the safe administration of cisplatin or carboplatin. In such patients, use of the PD-1 inhibitor pembrolizumab (Keytruda) had enough of a response rate for the agent to achieve FDA approval and routine use.
Then came data looking at the combination of pembrolizumab plus the nectin-4–targeting antibody–drug conjugate enfortumab vedotin (Padcev) that got everyone’s attention. Findings from phase 1 and 2 studies demonstrated that the combination produced objective response rates in the range of 65% to 73% with median duration of response exceeding 1 year. Based on these data, in early 2023 the FDA granted the combination an accelerated approval for patients not eligible for cisplatin-containing chemotherapy.
Of course, we all know that results of phase 2 trials are often not reproduced in randomized phase 3 trials. Enter EV-302/KEYNOTE KN-A39 (NCT04223856), whose data were presented at the ESMO meeting in October 2023. In the trial, 886 patients with previously untreated locally advanced or metastatic urothelial carcinoma were randomly assigned to receive platinum-based chemotherapy (gemcitabine plus either cisplatin or carboplatin) or enfortumab vedotin plus pembrolizumab (EV-P). Compared with the control arm, EV-P improved progression-free survival (median, 12.5 vs 6.3 months; HR, 0.45; P < .00001), overall survival (median, 31.5 vs 16.1 months; HR, 0.47; P < .00001), and objective response rate (68% vs 44%; P < .00001). It is hard to imagine that these astonishing results will not lead to the complete replacement of conventional chemotherapy as the standard first-line treatment for metastatic urothelial carcinoma.
Score another win for targeted therapies.
Leon-Ferre Explores Targeting of PIK3CA Alterations in ER+ Breast Cancer
July 24th 2024During a live Community Case Forum event in partnership with the Minnesota Society of Clinical Oncology, Roberto A. Leon-Ferre, MD, discussed drugs targeting PIK3CA alterations in patients with ER+ metastatic breast cancer.
Read More
Roundtable Roundup: Treatment for Metastatic pMMR Endometrial Cancer
July 23rd 2024In separate, live virtual events, Michael J. Birrer, MD, PhD, and Jubilee Brown, MD, surveyed participants on the treatment of a postmenopausal woman with stage IVA endometrial cancer after first-line chemotherapy.
Read More
George Explores Impact of Risk Status With Cabozantinib/Nivolumab in Advanced RCC
July 19th 2024During a Case-Based Roundtable® event, Daniel George, MD, discussed the results of the CheckMate 9ER trial across favorable, intermediate, and poor risk groups in patients with advanced renal cell carcinoma.
Read More
Depth of Response With Quadruplet Regimens Considered in Newly Diagnosed Multiple Myeloma
July 18th 2024During a Case-Based Roundtable® event, Timothy Schmidt, MD, and participants discussed treatment selection for a 54-year-old patient with transplant eligible R-ISS stage 2/R2-ISS stage 3 IgG-κ myeloma.
Read More
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More